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Abstract
Background: The internet portal http://www.brustkrebs-studien.de (BKS) was launched in 2000 by the German
Society of Senology (DGS) and the Baden-Württemberg Institute for Women’s Health (IFG) to provide expert-
written information on breast cancer online and to encourage and facilitate the participation of breast cancer
patients in clinical trials. We describe the development of BKS and its applications, and report on website statistics
and user acceptance.
Methods: Existing registries, including ClinicalTrials.gov, were analysed before we designed BKS, which combines a
trial registry, a knowledge portal, and an online second opinion service. An advisory board guided the process. Log
files and patient enquiries for trial participation and second opinions were analysed. A two-week user satisfaction
survey was conducted online.
Results: During 10/2005-06/2010, the portal attracted 702,655 visitors, generating 15,507,454 page views. By 06/
2010, the website’s active scientific community consisted of 189 investigators and physicians, and the registry
covered 163 clinical trial protocols. In 2009, 143 patients requested trial enrolment and 119 sought second
opinions or individual treatment advice from the expert panel. During the two-week survey in 2008, 5,702 BKS
visitors submitted 507 evaluable questionnaires. Portal acceptance was high. Respondents trusted information
correctness (80%), welcomed self-matching to clinical trials (79%) and planned to use the portal in the future (76%)
and recommend it to others (81%).
Conclusions: BKS is an established and trusted breast cancer information platform offering up-to-date resources
and protocols to the growing physician and patient community to encourage participation in clinical trials. Further
studies are needed to assess potential increases in trial enrolment by eligibility matching services.
Background
Breast cancer is the most common female malignancy in
Germany and worldwide, and its prevalence is predicted
to increase [1]. Growing numbers of clinical trials are
being conducted to collect the information needed to
provide patients with tailored treatments, and the guide-
lines for certified breast centres in Germany require that
20% of all treated patients be enrolled in clinical trials
[2]. However, trial recruitment is difficult, expensive and
time-consuming [3]. In the everyday clinical setting,
physicians recruit fewer than half of the potentially eligi-
ble patients into clinical trials [4]. Major factors prevent-
ing patients from participation have been shown to
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study treatment, concerns about work-related problems,
travel and long treatment periods [6,7]. Physicians fail to
recruit patients due to reservations about clinical trials
and negative referral policies at certain centres, and
their patients’ comorbidities, mental state and disabilities
[8,9]. In addition, the inclusion and exclusion criteria for
trials can vary to such an extent that physicians may not
have sufficient knowledge to identify eligible patients
[10]. On the other hand, 40-50% of cancer patients
already resort to the Internet for healthcare information,
and this number is likely to increase dramatically over
the next few years [4]. As a result of “patient empower-
ment”, patients have come to expect access to reliable,
high quality, patient-centred information on their medi-
cal condition and all available treatment options.
To meet these demands, the German Society of Senol-
ogy (DGS) and the Baden-Württemberg Institute for
Women’s Health (IFG) in 2000 jointly launched the
internet portal http://www.brustkrebs-studien.de (BKS)
as a not-for-profit service to breast cancer patients and
physicians alike [11,12], offering patients extensive infor-
mation on the disease, its treatment and study participa-
tion, and providing investigators with a registry database
for their clinical trials. We here describe how BKS was
developed and present the results of the implementation
phase as a proof of principle.
Methods
Development of the BKS website
Design of the BKS platform
Existing breast cancer trial registries such as Clincial-
Trials.gov (maintained by the National Cancer Institute
(NCI)), BreastCancerTrials.org, OncoLink.org and a
German clinical trials registry maintained by the
German Cancer Society, Studien.de, were reviewed and
analysed [13-16]. All features were compared, evaluated
and prioritized. These were reviewed by an advisory
board of breast cancer experts from the German Society
of Senology (DGS) and patient support and advocacy
organizations to assist with the development process.
The advisory board regularly reviewed drafts of BKS to
ensure early detection of usability issues as work
progressed.
Software implementation
HTML/PHP (Hypertext Markup Language/Hypertext
Preprocessor) and MySQL (Structured Query Language)
were chosen because they are well-established standards
and supported by virtually all web browsers. They also
offer the benefits of Open Source Software for maxi-
mum scalability and extensibility [17,18]. Security mea-
sures implemented included the encryption of data
transmitted to and from users via HTTPS/SSL (Hyper-
Text Transport Protocol Secure/Secure Sockets Layer)
and digital certificates [19]. User friendliness was given
the highest priority during the design and development
phase, in accordance with the findings of Nielsen [20].
Trial registry
A registry of all relevant therapeutic breast cancer trials,
including protocols, inclusion and exclusion criteria and
recruitment status was designed and implemented as
one of the three core BKS resources. The advisory
board determined the studies to be included in the reg-
istry. The principal investigators were assigned the
responsibility for maintaining and updating the informa-
tion on their trials. All trial entries underwent regular
quality assurance reviews by the DGS support team.
Breast cancer guidebook
To strengthen the portal as a knowledge hub on breast
cancer, the DGS published its patient-centred guidebook
on BKS.
Expert advice
A service was implemented via which patients could
contact an expert panel for second opinions or advice
on treatment and participation in clinical trials.
Evaluation of the BKS website
Access statistics
User and hit statistics were obtained by log file analysis
using the Webalizer 2.1 [21].
User interests, portal acceptance and satisfaction
A two-week online survey was conducted during the
2nd and 3rd week of March 2008. To this end, a ques-
tionnaire designed to assess user acceptance and satis-
faction was announced and made accessible on the BKS
homepage. The questionnaire comprised 29 questions
with Likert-type scale answers. The questions addressed
topics such as the reasons for visiting the website, infor-
mation quality, quantity and structure of content, aware-
ness of, and interest in, clinical trial participation, and
usability aspects of the portal, e.g. page loading time.
Statistical analysis
Descriptive statistics were performed using SPSS soft-
ware (version 9.0 for Windows; SPSS Inc, Chicago IL,
USA) to analyse the information submitted via the
online questionnaire.
Ethics
This study was noninterventional, and no patient-identi-
fiable data were used in the analyses. Therefore the
study did not require ethics committee approval or
informed patient consent according to the relevant
German laws and regulations.
Results
The BKS website
In 2000, the German Society of Senology (DGS)
launched the BKS portal http://www.brustkrebs-studien.
de as an information resource and a registry-based
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Page 2 of 9matching service for breast cancer patients to facilitate
their enrolment in clinical trials. Figure 1 is a schematic
representation of the website’sc o r ef e a t u r e st h a tc a nb e
accessed directly from the home page.
Figure 2 shows exemplary screenshots of the page on
the BKS portal where patients can match themselves to
relevant clinical trials, pages with search results and
study information as well as part of the input mask
principal investigators can access to register clinical
trials.
The three main components of the BKS portal and
their features and functionalities are described in the
following.
Trial registry
A consistent layout and step-by-step wizards were
implemented to help users familiarize themselves rapidly
with the system. Investigators receive immediate feed-
back on information validity when entering protocol
information, an approach also used in the NCI’sC l i n i -
calTrials.gov database [22]. Investigators can securely
publish classified trial documents for physicians via Doc-
Check® authentication [23]. An automated notification
system reminds investigators to update trial information
a n da l e r t sr e g i s t e r e dp a t i e n t st on e ws t u d i e sa ss o o na s
they are entered into the registry database. Potential
study centres can easily contact principal investigators
via the system to enquire about inclusion of their site in
the database.
Patients can search the trial registry for suitable clini-
cal trials via a simplified wizard-based matching service.
Three basic screening questions establish the patient’s
disease and treatment profile (Figure 2, panel A). The
search for suitable studies is then based upon individual
parameters and refined by specific criteria, such as treat-
ment modalities, anti-cancer drugs, trial status and ran-
domization type. Following the basic search, patients
can securely forward their details anonymously to a par-
ticular principal investigator for further eligibility testing.
Breast cancer guidebook
Written by prominent members of the DGS, this core
resource of the BKS portal provides detailed information
on the pathogenesis, types, prevalence, early detection
and diagnosis of breast cancer, treatment options, fol-
low-up care and support resources, while also including
interactive modules, such as an online audio book
("From diagnosis to follow-up care”) and 3D video ani-
mations. The guidebook is based on the high quality cri-
teria for health related websites [24]. Another section,
added to facilitate the provision of basic informed con-
sent, offers information on clinical trial participation,
Figure 1 Schematic representation of directly accessible core features on the BKS home page.
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as randomization and blinding, the quality of trials and
participants’ rights and obligations.
Expert advice
An expert advisory board of leading breast cancer spe-
cialists can be contacted via the platform for second opi-
nions and personal treatment recommendations with
regard to clinical trials.
Evaluation of the BKS website
Access statistics
Between 1 October 2005 and 30 June 2010, 702,655 visi-
tors logged onto the portal, generating a total of
15,507,454 page views (quarterly average: 46,183 visitors
[range 23,583-55,738]). Figure 3 shows access details
from the log file analysis. Mean website visit duration
was 3.2 minutes.
Figure 2 Screenshots of BKS. A: Patient search; to ensure usability, patients are guided through the wizard using six questions to determine
the need for adjuvant or neoadjuvant therapy; B: Personalized search results matching the patient’s profile; C: Example of the study information
given for an adjuvant chemotherapy trial, including details of the principal investigator, study design, recruitment status and study regimens;
D: Principal investigator’s input screen for entering details of a clinical trial.
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In 2009, 143 patient enquiries about trial participation
were securely forwarded to the principal investigators
for eligibility screening. In the same period, 119 patients
sought a second opinion or individual treatment advice
online via the expert panel.
User evaluation of BKS
The portal attracted 5,702 visitors during the two-week
online survey period. In total, 568 questionnaires were
submitted, of which 507 (89%) were evaluable. Visitors
were predominantly patients with breast cancer (67%) or
friends and relatives (25%). Most visitors stated that they
used the Internet as a source for information about
breast cancer (81%), and some regularly forwarded
information on the disease to others or exchanged such
information (33%).
Most participants found the information on BKS well
organized (79%), useful (79%), adequate (63%) and easy
to navigate through (87%). The most frequently accessed
content in the guidebook was information on the patho-
genesis and diagnosis of breast cancer (42%) and treat-
ment options (34%). Most users were confident that the
information offered was correct (80%). Pages loaded
quickly enough (83%).
More than three-quarters (83%) of respondents called
for a discussion forum as an additional feature to the
portal. About two-thirds (68%) stated they would be
happy to store their medical details online in an anon-
ymous breast cancer record and about three-quarters
(74%) were interested in communicating individually
with an expert (e.g. for a second opinion and treatment
options). Most visitors indicated that they intended to
use the portal again in the future (76%) and would
recommend it to others (81%).
Patient attitudes towards trial participation
Most patients considered it valuable to be able to search
for clinical trials themselves (79%), and a majority had
already considered trial participation (62%) and pre-
viously sought information on participation in clinical
trials (54%). The information sources on trial participa-
tion that respondents considered useful were the Inter-
net (29%), the patients’ physicians (27%) and other
patients or support groups (15%).
Trial registry
By 30 June 2010, a community of 189 investigators and
physicians was contributing to the portal, including all
major breast cancer trials groups in Germany, who reg-
ularly updated the information on their trials. At that
time, the registry covered 163 trials, of which 89 (55%)
investigated recurrent disease and 51 (31%) evaluated
adjuvant therapy, 15 (9%) neoadjuvant therapy, 4 radio-
therapy and 4 surgical treatment (2% each). No trials of
preventive interventions had been registered. The 89
(55%) of studies in patients with recurrent disease
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Figure 3 Log file analysis for 1 October 2005 to 30 June 2010
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Page 5 of 9comprised 27 (30%) with chemotherapy, 8 (9%) with
biologicals, 6 (7%) with endocrine treatment, 2 (2%)
with radiotherapy and 6 (7%) with other treatment
approaches. Of the 51 (31%) adjuvant trials 6 (12%)
used chemotherapy, 4 (8%) biologicals, 2 (4%) bispho-
sphonates, 3 (6%) endocrine treatment, and 1 (2%) other
treatments. Table 1 lists them o s tf r e q u e n t l yv i s i t e d
protocols during the 5-month period from 1 August to
12 December 2008.
Study types in the BKS registry compared with ClinicalTrials.
gov (NCI)
An analysis conducted in March 2008 showed that 52%
of the BKS trials were in patients with recurrent disease,
as opposed to only 2.3% of the NCI trials. The majority
(70%) of the NCI trials investigated neoadjuvant thera-
pies (26%), radiotherapy (20%) or surgical treatment
(24%).
Discussion
Over the past few decades, the concept of tailored treat-
ment for breast cancer has led to an ever-increasing
need for clinical studies, but patient enrolment has gen-
erally been too slow to meet the demands of valid
guidelines. As a result of patient empowerment, the
demands for reliable, patient-centred information have
also grown. The integration of the patient as an active
participant in the decision-making process and a partner
requiring comprehensive, up-to-date, correct, compre-
hensible information reflects the changing patient-physi-
cian relationship. The Internet has become a key source
for patients who wish to be well informed [25], and it
has been identified as a powerful vector in increasing
trial recruitment rates [4]. It has also been shown that
the knowledge- and data-intensive processes of deter-
mining patient eligibility can be facilitated by using
computerized systems [26]. Here, we describe how the
German Society of Senology (DGS) and the Baden-
Württemberg Institute for Women’sH e a l t h( I F G ) ,i n
collaboration with patient support and advocacy groups,
developed and established a trusted online information
and communication platform featuring up-to-date trial
protocols and resources for the growing physician and
patient community. Similar to the NCI’s ClinicalTrials.
gov, the BKS portal is an official resource backed by a
national specialist medical society and aims to serve
patients, doctors and researchers alike.
It is unrealistic to assume that physicians can screen
every patient for trial eligibility in view of the vast num-
ber of clinical trials available today. A large number of
potential participants are therefore lost. It has been sug-
gested that only 2-4% of patients with newly diagnosed
cancer participate in clinical trials [27]. Although online
trial registries seem to be a preferred solution to this
dilemma, trend analysis has ind i c a t e dt h a ti ti su n l i k e l y
that a single trial database would function worldwide,
enabling multiple domain-, funder- or country-specific
registers to be created [28].
Over the past few years, we have established the BKS
website as a highly frequented breast cancer portal with
a total of over 700,000 visitors by the middle of 2010.
On average, 46,183 visitors accessed the BKS portal per
quarter during the period from 1 October 2005 to
30 June 2010.
The true value of the BKS became apparent in 2009,
during which year 143 patients contacted investigators
via the website to enquire about trial enrolment and 119
requests for second opinions were submitted via the
secure e-messaging service. The benefits of e-messaging
have been widely discussed in the literature and include
decreased numbers of telephone calls [29], unnecessary
clinic visits [29-31], improved patient care [32], greater
efficiency in the exchange of information between physi-
cians and patients [29] and cost savings [33].
The respondents to our online survey showed a high
degree of satisfaction with both the design of the portal
and the information provided, and also expressed great
trust in the information. The great majority of respon-
dents stated that they would recommend the portal to
others and continue using it in the future. Patients have
been shown to respond positively to portals backed by a
national specialist medical society because they are per-
ceived as more trustworthy [34], and this is a likely rea-
son for the success of our portal, which is officially
supported by the German Society of Senology (DGS).
By the middle of 2010, the BKS covered a total of 163
current breast cancer trials, which the advisory board
Table 1 Most frequently visited trial protocols between 1 August and 31 December 2008
Study
acronym
Full study title Average
weekly hits
SUCCESS Simultaneous study of gemcitabine-docetaxel combination adjuvant treatment, as well as extended
bisphosphonate and surveillance-trial
1,548
GAIN - GBG
33
A study to compare ETC vs. EC-TX and ibandronate vs. observation in patients with node-positive primary breast
cancer
1,008
FACE Comparison trial of letrozole and anastrozole in the adjuvant treatment of postmenopausal women with hormone
receptor and node positive breast cancer
488
NATAN Postoperative use of zoledronic acid in breast cancer patients after neoadjuvant chemotherapy 469
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scientific BKS community at t h et i m ec o n s i s t e do f1 8 9
physicians and investigators. The majority of trials (55%)
focused on the use of chemotherapy in recurrent dis-
ease. However, the most visited trials were those investi-
gating adjuvant chemotherapy regimens. This is
especially relevant since the majority of trials registered
with the NCI during our study period were neoadjuvant
studies, possibly reflecting the future focus of research
in breast cancer trials.
The success of trial registries depends on a number of
factors. One of the main issues in the development of
the BKS portal was the need for up-to-date information
on trial status, which meant that principal investigators
had to take responsibility for updating the information
on their trials and removing closed trials from the data-
base. To achieve this, the system was equipped with an
automated notification and feedback service to encou-
rage commitment on the part of both the support team
and the investigators.
Studies suggest that female patients are generally in
favour of clinical trials [35,36], and this is supported by
our finding that almost two-thirds of the BKS visitors
considered participating in a trial. However, complex
trial descriptions and eligibility criteria, the extensive
use of medical terminology and expecting patients to
determine preferences early on in the registration pro-
cess act as strong barriers to trial participation [8].
Patients with previous clinical trial experience have
fewer concerns than those facing this option for the first
time, and recommendations by clinicians play a signifi-
cant role in their decision [10]. For these reasons, and
based on the suggestions of Gillen et al. [22], the
emphasis in the development of the BKS portal was
placed on patient-friendly versions of trial protocols
embedded into relevant patient information and sup-
ported by leading breast cancer experts. Our user analy-
sis showed that most patients appreciated being able to
search for suitable trials themselves, and that patients
relied on the Internet, and not their doctor, for informa-
tion on trials. To concentrate on patient-friendliness
and provide high-quality content was therefore the right
approach. To ensure that patients’ needs were addressed
appropriately, all development work was, and continues
to be, conducted in close collaboration with patient sup-
port and advocacy organizations, notably “Frauen-
selbsthilfe nach Krebs” (Women’sS e l f - H e l pa f t e r
Cancer) and “Mammazone”.
A further trend observed in our analysis is that patients
are interested in online personal health records, which is
consistent with earlier reports [10]. Although this trend
has been known for some years, no approach to patient
disease management has been successfully adopted at a
national level so far. The BreastCancerTrials.org service
[13], however, offers a promising approach. It functions
as an online patient breast cancer record combined with
a matching service to suitable trials. OnkoLink is a simi-
lar portal but is not breast cancer specific [37]. A match-
ing service for trial eligibility based on the US National
Cancer Institute’s Physician Data Query (PDQ) database
was introduced by Ohno-Machado et al. [38]. Not only
has it been shown that computer-based, automated
screening is superior to physician-based individual
screening [39], but also that an online system gives
patients more information and more time to decide, and
also increases their confidence in their decision-making
[40]. Before the BKS portal was initiated, no such
approach had been pursued in Germany for breast cancer
- a shortcoming that has now been addressed.
One of the limitations of online services for study
recruitment in this population is that female breast can-
cer most frequently occurs after the sixth decade of life,
at which age women may be less likely to use online
services. Moreover, minorities tend to be underserved
with regard to Internet access, especially in rural areas
[41]. Clinicians should therefore bear in mind that clini-
cal trial recruitment via the Internet may introduce bias
[42]. Thus, potential selection bias represented another
limitation to our user analysis. Further limitations
included the relatively small sample size, the short per-
iod during which the survey was conducted, and that it
is unclear whether the participants were representative
of the general population, e.g. with regard to age distri-
bution. Despite these limitations, we are confident that
the largely very positive answers from the respondents
confirmed our approach to launch the BKS portal and
that they provided useful information for further
enhancements to the service.
Web-based clinical trial portals have great potential as
a tool for physicians to manage an increasing number of
clinical studies and for patients to access accurate and
up-to-date information. Developed by a team physicians
and investigators, patient support and advocacy groups
and the German Society of Senology, the BKS website
already effectively meets the needs of all types of users
with regard to data security, privacy and ease of use. A
conceivable future refinement of our system will include
the creation of pools of eligible patients who have
expressed interest in clinical trial participation, under-
gone preliminary screening and given basic consent.
Work is in progress to expand the service by introdu-
cing a tool for cross-matching patient demographic and
clinical data with trial inclusion and exclusion criteria.
Integration of such services into hospital information
systems would greatly facilitate preliminary screening
and mean that a web-based tool of this kind could be
integrated into everyday clinical practice. Most impor-
tantly, outcome research is now needed to determine
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ment to clinical studies.
Conclusions
We conclude that http://www.brustkrebs-studien.de is
an established and trusted interactive platform providing
information on breast cancer for patients and physicians
alike. With the aim of encouraging participation in clini-
cal trials, it offers the growing community of patients
and physicians seeking information on the internet a
range of up-to-date resources including expert-written
content on the disease, current treatment options and
clinical trial protocols. Further studies are needed and
being undertaken to assess potential increases in trial
enrolment by eligibility matching services.
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